Sean Hocking
An Osoyoos-based firm has acquired approval to start out analysis into magic mushrooms.
Way2Grow Biopharma Corp. was given the inexperienced mild from Well being Canada to construct a psilocybin manufacturing facility, permitting them to acquire psychedelics in addition to propagate, domesticate, harvest and promote psychedelics to pharmacies, clinics and different licensed analysis services for allowable analysis functions.
Their new constructing might be on the identical property positioned within the Osoyoos industrial park that homes the enterprise’s hashish operations, which launched in 2018.
Plans are for the engineering and drafting of the constructing design to be accomplished via December, after which transfer into building into January, hoping to finish constructing by the tip of February, in keeping with firm CEO Jamie Filipuzzi.
“It’s principally at first going for use for analysis, there’s just a few docs proper now which are engaged on it with sufferers,” he defined.
“There are 15 docs, I consider, in Canada which are allowed to work with it, however solely on themselves whereas they determine it out earlier than it goes out to sufferers after which hospitals.”
For the reason that firm received its begin with analysis targeted on hashish and extraction, together with medical gross sales, Filipuzzi defined that it appeared pure to maneuver into magic mushrooms as their experience focuses on cultivation science and the plant science.
“We’re extra targeted simply on plant science and growth of the fungi and hashish.
I feel for ourselves, it’s only a pure match into organics with what we’re doing and shifting into biosynthetic and biotherapeutics to mix therapies.”
For now, the corporate will be unable to promoting their merchandise to anybody aside from medical docs, the hospitals and analysis centres.
